Colombel JF, Sandborn WJ, Schreiber S, Danese S, et al. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY). J Crohns Colitis 2025 Apr 17:jjaf060. doi: 10.1093.
PMID: 40243842